Literature DB >> 33546050

Standardized nursing management of enzyme replacement therapy for late-onset Pompe disease.

Shan Tang1,2, Jiachu Ma1, Huaxing Meng2, Junhong Guo2, Shuyan Cao2, Binquan Wang1.   

Abstract

ABSTRACT: Pompe disease or glycogen storage disease type II is a rare autosomal recessive disorder caused by a deficiency of the lysosomal enzyme a-glucosidase. Although enzyme replacement therapy (ERT) with 2 weekly intervals following was considered an effective treatment for Pompe disease in 2006, few patients can afford to receive treatment in China because of the high cost. This study aimed to examine the standard management of enzyme replacement therapy for late-onset Pompe disease among patients over the age of 14 years from a nursing perspective in order to assess operating procedures. ERT injection fluid dispensing and infusion procedures using different methods were analyzed and compared in 3 patients with advanced Pompe disease for forming standard operation procedures. In addition, the impact of different methods on time consumption was analyzed by 1-way analysis of variance. There were significant differences in time consumption between different dispensing and infusion methods. The time of dispensing and infusing the injection fluids using the cooperative method was 15.97 minutes shorter than that using the conventional method (95% CI: 4.51-27.43, P = .012); the time using the modified method was 20.93 minutes shorter than that using the conventional method (95% CI: 9.47-32.39, P = .012); and there was no significant difference between the cooperative and modified methods (P = .431). Enzyme replacement therapy entails frequent treatment and strict nursing requirements related to the intravenous infusion process. In this context, a standard operating procedure can be used to control nursing times and labor costs effectively while ensuring a safe and effective infusion process.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33546050      PMCID: PMC7837892          DOI: 10.1097/MD.0000000000024276

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  16 in total

1.  Standard Operating Procedure: use in nursing care in hospital services.

Authors:  Giselle Patrícia Guerrero; Lúcia Marinilza Beccaria; Maria Auxiliadora Trevizan
Journal:  Rev Lat Am Enfermagem       Date:  2008 Nov-Dec

Review 2.  The Brazilian consensus on the management of Pompe disease.

Authors:  Juan C Llerena; Dafne Maria Horovitz; Suely Kazue Nagahashi Marie; Gilda Porta; Roberto Giugliani; Maria Verónica Muñoz Rojas; Ana Maria Martins
Journal:  J Pediatr       Date:  2009-10       Impact factor: 4.406

Review 3.  Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel.

Authors:  Mark Tarnopolsky; Hans Katzberg; Basil J Petrof; Sandra Sirrs; Harvey B Sarnat; Kimberley Myers; Nicolas Dupré; Dubravka Dodig; Angela Genge; Shannon L Venance; Lawrence Korngut; Julian Raiman; Aneal Khan
Journal:  Can J Neurol Sci       Date:  2016-04-08       Impact factor: 2.104

4.  Short-term chronoamperometric screening of chlorpromazine-package interactions.

Authors:  B A Sarsfield; J T Maloy
Journal:  J Pharm Sci       Date:  1998-09       Impact factor: 3.534

5.  The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.

Authors:  P Laforêt; K Laloui; B Granger; D Hamroun; N Taouagh; J-Y Hogrel; D Orlikowski; F Bouhour; A Lacour; E Salort-Campana; I Penisson-Besnier; S Sacconi; F Zagnoli; F Chapon; B Eymard; C Desnuelle; J Pouget
Journal:  Rev Neurol (Paris)       Date:  2013-09-03       Impact factor: 2.607

Review 6.  Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease.

Authors:  Juan Clinton Llerena Junior; Osvaldo Jm Nascimento; Acary Souza B Oliveira; Mario Emilio T Dourado Junior; Carlo D Marrone; Heloise Helena Siqueira; Cláudia F R Sobreira; Elza Dias-Tosta; Lineu Cesar Werneck
Journal:  Arq Neuropsiquiatr       Date:  2015-12-22       Impact factor: 1.420

7.  24-months results in two adults with Pompe disease on enzyme replacement therapy.

Authors:  Stefan Vielhaber; Andrea Brejova; Grazyna Debska-Vielhaber; Joern Kaufmann; Helmut Feistner; Mircea A Schoenfeld; Friedemann Awiszus
Journal:  Clin Neurol Neurosurg       Date:  2011-04-07       Impact factor: 1.876

8.  Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults.

Authors:  T Merk; T Wibmer; C Schumann; S Krüger
Journal:  Eur J Neurol       Date:  2008-12-09       Impact factor: 6.089

9.  Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study.

Authors:  Laura E Case; Dwight D Koeberl; Sarah P Young; Deeksha Bali; Stephanie M DeArmey; Joanne Mackey; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2008-10-18       Impact factor: 4.797

10.  Adsorption of insulin onto infusion sets used in adult intensive care unit and neonatal care settings.

Authors:  Najam Zahid; Kevin M G Taylor; Hardyal Gill; Fiona Maguire; Rob Shulman
Journal:  Diabetes Res Clin Pract       Date:  2008-04-18       Impact factor: 5.602

View more
  2 in total

1.  Review on Comfort Nursing Interventions for Patients Undergoing Neurosurgery and General Surgery.

Authors:  Limin Wu; Yingfa Chen; Jin Zhang; Honglan Yu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-10       Impact factor: 2.650

2.  Nursing Skill Assessment of Hospital Nurses in Management of Critically Ill Patients.

Authors:  Lingli Xu; Qiyu Sun; Jiayi Feng; Li Jing Huang; Chunjing Xu; Weihong Shen; Jian Ding; Yongmei Jin
Journal:  Appl Bionics Biomech       Date:  2022-08-29       Impact factor: 1.664

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.